Immunic, Inc.
Immunic, Inc. (IMUX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IMUX · as of Sep 30, 2025
Ownership Breakdown
65
Institutional Holders
▲ 7 vs Q2
$37.64M
Total Inst. Value
▲ $2.63M vs Q2
9.87M
Shares Outstanding
freeFloat 96.88%
42.69M
13F Shares Held
▼ 7.49M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IMUX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ABRDN PLC pharmaceutical preparations | 8.24M | 6.24% | 6.24% | $7.27B | Nov 7, 2025 | — held |
BVF INC/IL pharmaceutical preparations | 7.65M | 5.79% | 5.79% | $6.75B | Nov 14, 2025 | — held |
AVIDITY PARTNERS MANAGEMENT LP pharmaceutical preparations | 4.70M | 3.56% | 3.56% | $4.14B | Nov 14, 2025 | ▼ 916.4K |
VANGUARD GROUP INC pharmaceutical preparations | 4.35M | 3.29% | 3.29% | $3.83B | Nov 7, 2025 | ▲ 220.0K |
MORGAN STANLEY pharmaceutical preparations | 3.10M | 2.35% | 2.35% | $2.74B | May 27, 2026 | ▼ 525.4K |
COLONY GROUP, LLC pharmaceutical preparations | 2.58M | 1.95% | 1.95% | $2.28B | Nov 14, 2025 | ▲ 39.1K |
LAURION CAPITAL MANAGEMENT LP pharmaceutical preparations | 1.88M | 1.42% | 1.42% | $1.66B | Nov 17, 2025 | ▼ 22.9K |
SOLEUS CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 1.58M | 1.20% | 1.20% | $1.39B | Nov 14, 2025 | ▼ 5.71M |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 1.40M | 1.06% | 1.06% | $1.23B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.03M | 78.21% | 78.21% | $911.65M | Nov 12, 2025 | ▲ 59.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
15
Increased
+2.13M shares9
New Positions
first time holders6
Decreased
−7.56M shares0
Sold Out
fully exitedNet shares change (top 50)
5.43M
+2.13M / −7.56M
Net new holders
+18
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IMUX insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lundgren Erik Chief Executive Officer | May 22, 2026 | Award | 1,000,000 | $13.05 | $13.05M | 1.00M | Form 4 ↗ |
Panzara Michael A. Chief Medical Officer | Apr 24, 2026 | Award | 300,000 | $8.80 | $2.64M | 300.0K | Form 4 ↗ |
Whaley Glenn Chief Financial Officer | Jul 16, 2025 | Award | 560,000 | $0.77 | $431.2K | 560.0K | Form 4 ↗ |
Whaley Glenn Chief Financial Officer | Jul 16, 2025 | Award | 280,000 | $0.77 | $215.6K | 280.0K | Form 4 ↗ |
Nash Duane Executive Chairman | Jul 16, 2025 | Award | 630,000 | $0.77 | $485.1K | 630.0K | Form 4 ↗ |
Nash Duane Executive Chairman | Jul 16, 2025 | Award | 315,000 | $0.77 | $242.6K | 315.0K | Form 4 ↗ |
Vitt Daniel CEO and Director | Jul 16, 2025 | Award | 1,720,000 | $0.77 | $1.32M | 1.72M | Form 4 ↗ |
Vitt Daniel CEO and Director | Jul 16, 2025 | Award | 860,000 | $0.77 | $662.2K | 860.0K | Form 4 ↗ |
Muehler Andreas Chief Medical Officer | Jul 16, 2025 | Award | 660,000 | $0.77 | $508.2K | 660.0K | Form 4 ↗ |
Muehler Andreas Chief Medical Officer | Jul 16, 2025 | Award | 330,000 | $0.77 | $254.1K | 330.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Immunic, Inc. (IMUX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 3.12%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Immunic, Inc. is ABRDN PLC, holding approximately 8.24 million shares — equal to 6.24% of outstanding shares — as of September 30, 2025.
A total of 65 institutional investors currently hold IMUX stock, with a combined institutional value of approximately $37,637,800 as of the most recent 13F filing period.
Frequently asked questions
IMUX ownershipImmunic, Inc. (IMUX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is ABRDN PLC with a 6.24% stake. Company insiders hold 3.12%. Data sourced from SEC Form 13F as of September 30, 2025.